Literature DB >> 9823977

Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer.

M A Chapman1, D Buckley, D B Henson, N C Armitage.   

Abstract

Evidence as to the value of preoperative carcinoembryonic antigen (CEA) in guiding treatment for patients with colorectal cancer is conflicting. The aim of this prospective study was to investigate the value of preoperative CEA in predicting tumour factors of proven prognostic value and long-term survival in patients undergoing surgery for colorectal cancer. Preoperative serum CEA, tumour ploidy, stage and grade were ascertained in 277 patients undergoing colorectal cancer surgery. This cohort of patients were followed up for a minimum of 5 years, or until death, in a dedicated colorectal clinic. Patients with an elevated CEA had a 5 year survival of 39%. This increased to 57% if the CEA was normal (P=0.001). The proportion of patients with a raised CEA increased with a more advanced tumour stage (P < 0.000001) and a poorly differentiated tumour grade (P < 0.005). Once stage had been controlled for, CEA was not a predictor of survival. No relationship between tumour ploidy and CEA was found. In conclusion, a raised preoperative serum CEA is likely to be associated with advanced tumour stage and poor long-term survival, compared with patients with a normal value.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823977      PMCID: PMC2063189          DOI: 10.1038/bjc.1998.682

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  20 in total

1.  Clinicopathological assessment and staging of colorectal cancer.

Authors:  N S Williams; J R Jass; J D Hardcastle
Journal:  Br J Surg       Date:  1988-07       Impact factor: 6.939

2.  Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.

Authors:  M Eskelinen; P Pasanen; A Kulju; E Janatuinen; P Miettinen; E Poikolainen; R Tarvainen; P Nuutinen; M Pääkkönen; E Alhava
Journal:  Anticancer Res       Date:  1994 May-Jun       Impact factor: 2.480

3.  Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer.

Authors:  H J Wanebo; B Rao; C M Pinsky; R G Hoffman; M Stearns; M K Schwartz; H F Oettgen
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

4.  A prospective evaluation of the effect of tumor cell DNA content on recurrence in colorectal cancer.

Authors:  N C Armitage; K C Ballantyne; J P Sheffield; P Clarke; D F Evans; J D Hardcastle
Journal:  Cancer       Date:  1991-05-15       Impact factor: 6.860

5.  Prognostic value of CA 19.9 levels in colorectal cancer.

Authors:  X Filella; R Molina; J J Grau; J M Piqué; J C Garcia-Valdecasas; E Astudillo; A Biete; J M Bordas; A Novell; E Campo
Journal:  Ann Surg       Date:  1992-07       Impact factor: 12.969

6.  The use of preoperative plasma CEA levels for the Stratification of patients after curative resection of colorectal cancers.

Authors:  R Goslin; G Steele; J Macintyre; R Mayer; P Sugarbaker; K Cleghorn; R Wilson; N Zamcheck
Journal:  Ann Surg       Date:  1980-12       Impact factor: 12.969

7.  The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer.

Authors:  C G Moertel; J R O'Fallon; V L Go; M J O'Connell; G S Thynne
Journal:  Cancer       Date:  1986-08-01       Impact factor: 6.860

8.  Serum carcinoembryonic antigen and DNA ploidy in colorectal carcinoma. A prospective study.

Authors:  M Kouri; S Pyrhönen; J P Mecklin; H Järvinen; A Laasonen; K Franssila; P Kuusela; S Nordling
Journal:  Scand J Gastroenterol       Date:  1991-08       Impact factor: 2.423

9.  CEA as a prognostic factor in colorectal cancer.

Authors:  X Filella; R Molina; J M Piqué; J J Grau; J C Garcia-Valdecasas; A Biete; F Novell; E Astudillo; J M Bordas; E Campo
Journal:  Anticancer Res       Date:  1994 Mar-Apr       Impact factor: 2.480

Review 10.  Value of carcinoembryonic antigen in the management of colorectal cancer.

Authors:  J Y Wang; R Tang; J M Chiang
Journal:  Dis Colon Rectum       Date:  1994-03       Impact factor: 4.585

View more
  22 in total

1.  [Clinical utility of serous tumoural markers].

Authors:  A Martín Suárez; L Alonso Díaz; I Ordiz Alvarez; J Vázquez; F Vizoso Piñeiro
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

2.  Low nutritional prognostic index correlates with poor survival in patients with stage IV colorectal cancer following palliative resection of the primary tumor.

Authors:  Kiyoshi Maeda; Masatsune Shibutani; Hiroshi Otani; Hisashi Nagahara; Kenji Sugano; Teturo Ikeya; Naoshi Kubo; Ryosuke Amano; Kenjiro Kimura; Kazuya Muguruma; Hiroaki Tanaka; Kosei Hirakawa
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

3.  Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer.

Authors:  Tsutomu Namikawa; Yasuhiro Kawanishi; Kazune Fujisawa; Eri Munekage; Jun Iwabu; Masaya Munekage; Hiromichi Maeda; Hiroyuki Kitagawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Surg Today       Date:  2017-10-17       Impact factor: 2.549

4.  Value of carcinoembryonic antigen assay in predicting hepatic metastases, local recurrence, and survival after curative resection of colorectal cancer.

Authors:  Ioannis Kanellos; Emmanouil Zacharakis; Haralampos Demetriades; Emmanouil Christoforidis; Dimitrios Kanellos; Manousos-Georgios Pramateftakis; Dimitrios Betsis
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

5.  Angiopoietin-like protein 2 as a potential biomarker for colorectal cancer.

Authors:  Takuma Yoshinaga; Takamasa Shigemitsu; Hiroto Nishimata; Masaki Kitazono; Emiko Hori; Ayako Tomiyoshi; Takayuki Takei; Masahiro Yoshida
Journal:  Mol Clin Oncol       Date:  2015-06-10

6.  [Present treatment strategies for rectal carcinoma].

Authors:  T Liersch; C Langer; B M Ghadimi; H Becker
Journal:  Chirurg       Date:  2005-03       Impact factor: 0.955

7.  Predictive factors associated with relapse of stage II/III colon cancer treated with peroral anti-cancer agents in the adjuvant setting.

Authors:  Yusuke Mizuuchi; Yoshitaka Tanabe; Masafumi Sada; Yoshiki Kitaura; Shuntaro Nagai; Yusuke Watanabe; Sadafumi Tamiya; Kinuko Nagayoshi; Kenoki Ohuchida; Toru Nakano; Masafumi Nakamura
Journal:  Mol Clin Oncol       Date:  2021-04-15

8.  Survival in Resected Stage II Colorectal Cancer Is Dependent on Tumor Depth, Vascular Invasion, Postoperative CEA Level, and The Number of Examined Lymph Nodes.

Authors:  Hsiang-Lin Tsai; Ching-Wen Huang; Chao-Wen Chen; Yung-Sung Yeh; Cheng-Jen Ma; Jaw-Yuan Wang
Journal:  World J Surg       Date:  2016-04       Impact factor: 3.352

Review 9.  From the genome to the proteome--biomarkers in colorectal cancer.

Authors:  Jens K Habermann; Franz G Bader; Christian Franke; Kaja Zimmermann; Timo Gemoll; Britta Fritzsche; Thomas Ried; Gert Auer; Hans-Peter Bruch; Uwe J Roblick
Journal:  Langenbecks Arch Surg       Date:  2007-10-16       Impact factor: 3.445

10.  Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment.

Authors:  Li-Chu Sun; Koung-Shing Chu; Su-Chen Cheng; Chien-Yu Lu; Chao-Hung Kuo; Jan-Sing Hsieh; Ying-Ling Shih; Shun-Jen Chang; Jaw-Yuan Wang
Journal:  BMC Cancer       Date:  2009-08-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.